Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mian Xi

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Scientific Reports|December 17, 2015
Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinomaLi-Ling Luo, Lei Zhao, Ying-Xue Wang, et al.
Annals of Medicine|February 2, 2026
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomesPeiying Cen, Biqi Chen, Wenxi Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled TrialMian Xi, Zhoutian Yang, Li Hu, et al.
Journal of Translational Medicine|December 13, 2012
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3Lei Zhao, Li-Ru He, Mian Xi, et al.
Ebiomedicine|November 26, 2022
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinomaJing Wen, Shuogui Fang, Yi Hu, et al.
Cancer Biology & Medicine|April 16, 2026
Machine learning-based clinical decision support tool for advanced ESCC in the immunotherapy era: a multi-center studyHui Bai, Xiaofeng Wang, Qifeng Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2020
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010Shiliang Liu, Jing Wen, Hong Yang, et al.
Journal for Immunotherapy of Cancer|January 12, 2026
Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trialsBaoQing Chen, Junying Chen, Sifen Wang, et al.
Annals of Surgery|January 16, 2018
Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and OutcomesMian Xi, Yadi Yang, Li Zhang, et al.
Cancers|August 8, 2019
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching StudyYang-Xun Pan, Mian Xi, Yi-Zhen Fu, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Scientific Reports|December 17, 2015
Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinomaLi-Ling Luo, Lei Zhao, Ying-Xue Wang, et al.
Annals of Medicine|February 2, 2026
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomesPeiying Cen, Biqi Chen, Wenxi Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled TrialMian Xi, Zhoutian Yang, Li Hu, et al.
Journal of Translational Medicine|December 13, 2012
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3Lei Zhao, Li-Ru He, Mian Xi, et al.
Ebiomedicine|November 26, 2022
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinomaJing Wen, Shuogui Fang, Yi Hu, et al.
Cancer Biology & Medicine|April 16, 2026
Machine learning-based clinical decision support tool for advanced ESCC in the immunotherapy era: a multi-center studyHui Bai, Xiaofeng Wang, Qifeng Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2020
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010Shiliang Liu, Jing Wen, Hong Yang, et al.
Journal for Immunotherapy of Cancer|January 12, 2026
Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trialsBaoQing Chen, Junying Chen, Sifen Wang, et al.
Annals of Surgery|January 16, 2018
Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and OutcomesMian Xi, Yadi Yang, Li Zhang, et al.
Cancers|August 8, 2019
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching StudyYang-Xun Pan, Mian Xi, Yi-Zhen Fu, et al.
Pageof 11